During the corresponding time, Clene Inc recorded a revenue increase by 233.33 % year on year, sequentially revenue grew by 500 %. While revenue at the Clene Inc 's corporate clients
Clene Inc. Advances ALS Treatment with Promising Phase 2 Clinical Data Submission to FDA In a significant advance in the fight against amyotrophic lateral sclerosis (ALS), Clene Inc. (Nasdaq: CLNN) reported the submission of new CNM-Au8 biomarker and clinical efficacy data to the U.S. Food and Drug Administration (FDA). This development marks another crucial step for Clene Inc., a clinical-stage biopharmaceutical company, and its wholly-owned subsidiary Clene Nanomedicine Inc., both of which are dedicated to improving mitochondrial health and protecting neuronal function to treat debilitating neurological conditions, including ALS and multiple sclerosis (MS). Background: A Beacon of Hope in Neurodegenerative...
Clene Inc. Unveils Promising Data from CNM-Au8 at ENCALS 2024, Celebrating Key Milestones and Future Directions Clene Inc. (Nasdaq: CLNN), along with its wholly owned subsidiary Clene Nanomedicine Inc., continues to fortify its position in the biopharmaceutical landscape by pioneering treatments aimed at improving mitochondrial health and safeguarding neuronal functionality. Their therapeutic portfolio, primarily focusing on neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS), Parkinson s disease, and multiple sclerosis (MS), is geared towards addressing some of the most pressing medical challenges of our time. At the 2024 European Network for the Cure of ALS (ENCALS) Meeting in Stockholm...
In a recent press release, IBN, a renowned communications organization specializing in connecting public companies with the investment community, announced the participation of Rob Etherington, the President, Director, and CEO of Clene Inc., on the First in Human podcast. This biotech-focused podcast features in-depth interviews with industry leaders and investors, shedding light on their journeys towards conducting in-human clinical trials. This article aims to provide an extensive overview of the press release, highlighting Clene Inc. s groundbreaking advancements in biopharmaceutical research.The Journey of Clene Inc. and CEO Rob EtheringtonClene Inc., a clinical-stage biopharmaceutical company, has garne...
Sources:
Clene Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Clene Inc’s corporate clients.
For your research, we’ve provided 9 tables on Clene Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
116.67 %